[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112012006644A2 - composto,método de tratamento de um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal, composição farmacêutica, uso de um composto e kit - Google Patents

composto,método de tratamento de um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal, composição farmacêutica, uso de um composto e kit

Info

Publication number
BR112012006644A2
BR112012006644A2 BR112012006644A BR112012006644A BR112012006644A2 BR 112012006644 A2 BR112012006644 A2 BR 112012006644A2 BR 112012006644 A BR112012006644 A BR 112012006644A BR 112012006644 A BR112012006644 A BR 112012006644A BR 112012006644 A2 BR112012006644 A2 BR 112012006644A2
Authority
BR
Brazil
Prior art keywords
disorder
compound
neurotransmitter
kit
treating
Prior art date
Application number
BR112012006644A
Other languages
English (en)
Inventor
Parasmal Jain Rajendra
Chakravarty Sarvajit
Original Assignee
Medivation Neurology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Neurology Inc filed Critical Medivation Neurology Inc
Publication of BR112012006644A2 publication Critical patent/BR112012006644A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112012006644A 2009-09-23 2010-09-23 composto,método de tratamento de um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal, composição farmacêutica, uso de um composto e kit BR112012006644A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24514809P 2009-09-23 2009-09-23
PCT/US2010/050079 WO2011038162A1 (en) 2009-09-23 2010-09-23 Pyrido(3,4-b)indoles and methods of use

Publications (1)

Publication Number Publication Date
BR112012006644A2 true BR112012006644A2 (pt) 2019-09-24

Family

ID=43796210

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012006644A BR112012006644A2 (pt) 2009-09-23 2010-09-23 composto,método de tratamento de um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal, composição farmacêutica, uso de um composto e kit

Country Status (8)

Country Link
US (2) US20130137705A1 (pt)
EP (1) EP2480079A4 (pt)
JP (1) JP5791611B2 (pt)
CN (1) CN102711467A (pt)
AU (1) AU2010298167B2 (pt)
BR (1) BR112012006644A2 (pt)
CA (1) CA2775129A1 (pt)
WO (1) WO2011038162A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
RU2544856C2 (ru) * 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP2274307B1 (en) 2008-03-24 2015-07-29 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
CN104387382A (zh) 2008-03-24 2015-03-04 梅迪维新技术公司 吡啶并[3,4-b]吲哚和应用方法
WO2010051503A1 (en) 2008-10-31 2010-05-06 Medivation Technologies, Inc. Azepino [4, 5-b] indoles and methods of use
CA2742320A1 (en) 2008-10-31 2010-05-06 Medivation Technologies, Inc. Pyrido[4,3-b]indoles containing rigid moieties
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
AU2010203356B2 (en) 2009-01-09 2015-11-26 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2010127177A1 (en) 2009-04-29 2010-11-04 Medivation Technologies, Inc. Pyrido [4,3-b] indoles and methods of use
EP2424366B1 (en) 2009-04-29 2016-02-17 Medivation Technologies, Inc. Pyrido [4, 3-b]indoles and methods of use
EP2480078A4 (en) 2009-09-23 2013-03-06 Medivation Technologies Inc PYRIDO- [4,3-B] INDOLE AND USE METHOD THEREFOR
EP2480081A4 (en) 2009-09-23 2013-03-06 Medivation Technologies Inc Bridged heterocyclic compounds and methods for their use
WO2011038163A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[3,4-b]indoles and methods of use
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103485A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011103433A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011103430A1 (en) 2010-02-19 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
AU2011274787B2 (en) 2010-07-07 2016-06-16 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2012112964A2 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
US20140155384A1 (en) 2011-02-18 2014-06-05 Medivation Technologies, Inc. Compounds and methods of treating diabetes
AU2012254158B2 (en) 2011-02-18 2016-02-04 Medivation Technologies, Inc. Compounds and methods of treating diabetes
US20140303144A1 (en) 2011-02-18 2014-10-09 Medivation Technologies, Inc. Compounds and methods of treating hypertension
AU2013305591B2 (en) 2012-08-24 2017-04-13 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9902713B2 (en) 2013-11-11 2018-02-27 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
CN104839184A (zh) * 2015-04-18 2015-08-19 广东中迅农科股份有限公司 含有氯吡嘧磺隆和氯氨吡啶酸以及烟嘧磺隆的农药组合物
WO2019090001A1 (en) * 2017-11-02 2019-05-09 California Institute Of Technology Neurokinin antagonists and uses thereof
EP3703716A4 (en) 2017-11-02 2021-12-01 California Institute of Technology EXPRESSION OF NEUROPEPTIDES
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2642438A (en) * 1949-07-15 1953-06-16 Hoffmann La Roche Pyridindoles and method of manufacture
GB721171A (en) * 1951-04-30 1954-12-29 Bayer Ag Derivatives of ª‰- and ª†- carbolines
JPS3922979B1 (pt) * 1962-04-10 1964-10-15
JPS3920857B1 (pt) * 1962-05-17 1964-09-24
JPS412713B1 (pt) * 1963-08-30 1966-02-21
US4754038A (en) * 1987-02-26 1988-06-28 American Home Products Corporation Carboline histamine H1 antagonists
US5817756A (en) * 1993-09-09 1998-10-06 Scios Inc. Pseudo- and non-peptide bradykinin receptor antagonists
ES2148347T3 (es) * 1993-09-09 2000-10-16 Scios Inc Antagonistas del receptor de la bradiquinina pseudo y no peptidica.
US5688807A (en) * 1994-03-11 1997-11-18 Eli Lilly And Company Method for treating 5HT2B receptor related conditions
WO1995024200A1 (en) * 1994-03-11 1995-09-14 Eli Lilly And Company Method for treating 5ht2b receptor related conditions
ES2182975T3 (es) * 1995-05-05 2003-03-16 British Tech Group Int Nueva quimica heterociclica.
GB9604996D0 (en) * 1996-03-08 1996-05-08 Black James Foundation Benzodiazonine derivatives
FR2771095B1 (fr) * 1997-11-14 1999-12-17 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1043991A4 (en) * 1997-11-14 2005-02-02 Lilly Co Eli TREATMENT OF ALZHEIMER DISEASE
DK1057814T3 (da) * 1997-12-25 2005-07-04 Meiji Seika Kaisha Tetrahydrobenzindolderivater
FR2796644B1 (fr) * 1999-07-23 2001-09-07 Adir Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
WO2004113336A1 (en) * 2003-06-16 2004-12-29 Chroma Therapeutics Limited Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
JP4671123B2 (ja) * 2003-06-23 2011-04-13 小野薬品工業株式会社 新規三環性複素環化合物
EP1714961B1 (en) * 2004-02-12 2015-12-09 Mitsubishi Tanabe Pharma Corporation Indazole compound and pharmaceutical use thereof
WO2006011750A1 (en) * 2004-07-27 2006-02-02 C & C Research Laboratories Tetrahydro-beta-carbolinone derivatives and process for preparing the same
US7772245B2 (en) * 2005-02-14 2010-08-10 Miikana Therapeutics, Inc. Inhibitors of histone deacetylase
JP5287257B2 (ja) * 2007-02-07 2013-09-11 アステラス製薬株式会社 アシルグアニジン誘導体
DE102007009264A1 (de) * 2007-02-26 2008-08-28 Ellneuroxx Ltd. 9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen
CA2683453C (en) * 2007-04-05 2013-06-11 Alla Chem, Llc Substituted 2,3,4,5-tetrahydro-1h-pyrido[4,3-.beta.]indoles, methods for the production and use thereof
RU2007139634A (ru) * 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
EP2179999A4 (en) * 2007-12-18 2011-06-08 Univ Toyama Nat Univ Corp CONDENSED TRICYCLIC COMPOUND WITH ALDOSIS REDUCTASE HARMFUL EFFECT
RU2544856C2 (ru) * 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN104387382A (zh) * 2008-03-24 2015-03-04 梅迪维新技术公司 吡啶并[3,4-b]吲哚和应用方法
TW201038569A (en) * 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy

Also Published As

Publication number Publication date
WO2011038162A1 (en) 2011-03-31
EP2480079A4 (en) 2015-04-08
US20130137705A1 (en) 2013-05-30
JP2013505946A (ja) 2013-02-21
CN102711467A (zh) 2012-10-03
EP2480079A1 (en) 2012-08-01
JP5791611B2 (ja) 2015-10-07
AU2010298167B2 (en) 2015-12-24
AU2010298167A1 (en) 2012-04-12
CA2775129A1 (en) 2011-03-31
US20130123277A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
BR112012006644A2 (pt) composto,método de tratamento de um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal, composição farmacêutica, uso de um composto e kit
BR112012006640A2 (pt) composto, composição farmacêutica, método de tratamento de um distúrbio cognitivo, distúrbiopsocótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal e kit
BR112012006648A2 (pt) composto,método de tratamento de um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal, composição farmacêutica e kit
BR112012006646A2 (pt) composto, composição farmacêutica, método de tratamento de um distùrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal e kit
BRPI0906244A2 (pt) Composto, composição farmacêutica, método para tratar um distúrbio cognitivo, psicótico, mediado por neurotransmissores ou um distúrbio neuronal em um indivíduo, uso de um composto e kit
BRPI0906245A2 (pt) Composto, método para tratar um distúrbio cognitivo, psicótico, mediado por neurotransmissor ou um distúrbio neuronal em indivíduo, uso de um composto, composição farmacêutica e kit
BRPI0816582A2 (pt) Composto, método para tratar um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou distúrbio neuronal em um indivíduo, composição farmacêutica, uso de um composto e kit
BRPI0818244A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI1010798A2 (pt) fechamento, aparelho de retenção, e método de uso do mesmo
BR112013022927A2 (pt) composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
BRPI0917458A2 (pt) composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0810082A2 (pt) 3-imidazolil-indóis para o tratamento de doenças proliferativas
BRPI1008383A2 (pt) composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
BRPI0918693A2 (pt) dispositivos para amostragem e métodos para concentração de microorganismos
BRPI0907976A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
BRPI0820474A2 (pt) método de tratamento de uma doença, uso de composto, e, composto
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BRPI0907974A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI1015014A2 (pt) composto, composição farmacêutica , e, método de tratamento de distúrbio(s) cognitivo(s) ou indicações com déficit(s) em cognição
BR112012020585A2 (pt) composto, composição farmacêutica e método de tratamento de um distúrbio mediado por tirosina quinase
EP2174914A4 (en) PROCESS FOR TREATING DIARSENIC TRIOXIDE
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
DK2164572T3 (da) Carbamoyl-cyclohexaner til behandling af akut mani

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B25I Requirement for requested change of headquarter

Owner name: MEDIVATION NEUROLOGY, INC. (US)

Free format text: A FIM DE ATENDER A ALTERACAO DE ENDERECO REQUERIDA ATRAVES DA PETICAO NO 18140006063 DE 13/03/2014, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O NOME DA EMPRESA DEPOSITANTE E O NOME DA EMPRESA QUE TEVE SEU ENDERECO ALTERADO.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B25E Requested change of name of applicant rejected

Owner name: MEDIVATION NEUROLOGY, INC. (US)

Free format text: INDEFERIDO(S) O(S) PEDIDO(S) DE ALTERACAO(OES) DE NOME CONTIDO(S) NA PETICAO 018140006063 DE 13/03/2014 EM VIRTUDE DO DESPACHO PUBLICADO NA RPI NO 2559 DE 21/01/2020.